Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Consensus on the practical use of amisulpride, an atypical antipsychotic, in the treatment of schizophrenia
Autore:
Lecrubier, Y; Azorin, M; Bottai, T; Dalery, J; Garreau, G; Lemperiere, T; Lisoprawski, A; Petitjean, F; Vanelle, JM;
Indirizzi:
Hop La Pitie Salpetriere, INSERM, U302, F-75013 Paris, France Hop La PitieSalpetriere Paris France F-75013 302, F-75013 Paris, France Ctr Hosp St Anne, Paris, France Ctr Hosp St Anne Paris FranceCtr Hosp St Anne, Paris, France Ctr Hosp St Marguerite, Marseille, France Ctr Hosp St Marguerite Marseille France t Marguerite, Marseille, France CHU La Colombiere, Montpellier, France CHU La Colombiere Montpellier France La Colombiere, Montpellier, France Ctr Hosp Specialise Vinatier, Bron, France Ctr Hosp Specialise Vinatier Bron France cialise Vinatier, Bron, France
Titolo Testata:
NEUROPSYCHOBIOLOGY
fascicolo: 1, volume: 44, anno: 2001,
pagine: 41 - 46
SICI:
0302-282X(2001)44:1<41:COTPUO>2.0.ZU;2-9
Fonte:
ISI
Lingua:
ENG
Soggetto:
NEGATIVE SYMPTOMS; RECEPTOR ANTAGONIST; ACUTE EXACERBATIONS; LIMBIC SELECTIVITY; IMPROVEMENT; HALOPERIDOL; SAFETY;
Keywords:
amisulpride; atypical antipsychotics; schizophrenia; consensus; switching; acute and chronic treatment; negative symptoms; positive symptoms;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Life Sciences
Citazioni:
12
Recensione:
Indirizzi per estratti:
Indirizzo: Lecrubier, Y Hop La Pitie Salpetriere, INSERM, U302, Pavillon Clerambault,47 Blvd Hop, F-75013 Paris, France Hop La Pitie Salpetriere Pavillon Clerambault,47 Blvd Hop Paris France F-75013
Citazione:
Y. Lecrubier et al., "Consensus on the practical use of amisulpride, an atypical antipsychotic, in the treatment of schizophrenia", NEUROPSYCHB, 44(1), 2001, pp. 41-46

Abstract

Clinical expectations in schizophrenia treatment have greatly increased since the introduction of new atypical antipsychotics, but the choice of therapeutic strategy has become more complex and reference guidelines are scarce. This paper summarizes the consensus of a broad range of professionals after long-term commercialization in France of an atypical antipsychotic, amisulpride. Participants were from psychiatric hospitals, private clinics, out-patients settings and research; all were experienced with the drug. Discussions focused on the practical use of amisulpride, as, in addition to the double-blind trials information, it may be useful for psychiatrists of other countries to intuitively understand the therapeutic properties of amisulpride. The topics selected include acute psychotic episodes, short- and long-term follow-up, feasibility of treating the initial phase, the elderly andswitching treatments. The French experience emphasizes the central role ofamisulpride as a first-line treatment of schizophrenia. Copyright (C) 2001S. Karger AG, Basel.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 25/01/20 alle ore 16:45:21